KC-3565

MC38-CCR7 Cell Line

×
34500
Home » MC38-CCR7 Cell Line

Background of MC38-CCR7 Cell Line

CCR7 encodes C-C motif chemokine receptor 7 and is also known as BLR2. This receptor was identified as a gene induced by the Epstein-Barr virus (EBV), and is thought to be a mediator of EBV effects on B lymphocytes. This receptor is expressed in various lymphoid tissues and activates B and T lymphocytes. It has been shown to control the migration of memory T cells to inflamed tissues, as well as stimulate dendritic cell maturation. The chemokine (C-C motif) ligand 19 (CCL19/ECL) has been reported to be a specific ligand of this receptor. Signals mediated by this receptor regulate T cell homeostasis in lymph nodes, and may also function in the activation and polarization of T cells, and in chronic inflammation pathogenesis. Alternative splicing of this gene results in multiple transcript variants.

Specifications

Catalog NumberKC-3565
Cell Line NameMC38-CCR7 Cell Line
NCBI/UniProt Accession NumberNM_001838.4
Clone Number23#
Host Cell LineMC38-KYBC
DescriptionMC38-CCR7 is a stable engineered cell line expressing human CCR7
QuantityOne vial of frozen cells (≥2×10⁶ cells/vial)
StabilityStable in culture over a minimum of 10 passages
ApplicationDrug screening and biological assays
Freezing Medium70% DMEM+20% FBS+10% DMSO
Propagation MediumDMEM+10%FBS+5μg/mL Puromycin
Selection MarkerPuromycin
MorphologyEpithelial
SubcultureSplit at a ratio of 1:4–1:6 every 2–3 days
Incubation37 °C with 5% CO₂
StorageLiquid nitrogen immediately upon receiving
Doubling TimeEstimated 19–36 hours
Mycoplasma StatusNegative
In Vivo ValidationNA

Cell Line Generation

MC38-CCR7 cell line was generated using a lentiviral vector expressing the human CCR7 sequence.

Characterization

Figure 1: Characterization of CCR7 overexpression in the MC38-CCR7 stable clone using FACS.

Figure 2: Characterization of CCR7 in the MC38-CCR7 stable clone using PCR sequencing.

Cell Resuscitation

  1. Pre-warm complete culture medium (basal medium and 10% FBS) in a 37°C water bath.
  2. Rapidly thaw the cryovial in a 37°C water bath for 1-2 minutes with gentle agitation.
  3. Transfer the vial to a biosafety cabinet, and disinfect the exterior with 70% ethanol.
  4. Aseptically transfer the cell suspension dropwise into a sterile centrifuge tube containing 9.0 mL of pre-warmed complete medium.
  5. Centrifuge at approximately 125 × g for 5–7 minutes at room temperature, carefully aspirate the supernatant without disturbing the cell pellet.
  6. Gently resuspend the pellet in an appropriate volume of complete medium and transfer the suspension into a T25 flask.
  7. Incubate the flask in a 37°C in a humidified 5% CO₂ incubator.
  8. Assess cell viability and morphology after 24 hours. If cells appear healthy, replace the medium with fresh medium supplemented with the appropriate selective antibiotic.
  9. Subculture the cells at a ratio of 1:4–1:6 every 2–3 days upon reaching 80%–90% confluency.

Cell Freezing

  1. Prepare the freezing medium (70% basal medium, 20% FBS and 10% DMSO) freshly before use.
  2. Pre-chill the freezing medium on ice and label the cryovials accordingly.
  3. Transfer the cell suspension to a sterile conical tube and perform a cell count to determine total viability and density.
  4. Centrifuge the cells at 250×g for 5 minutes at room temperature; carefully aspirate the supernatant.
  5. Gently resuspend the pellet in chilled freezing medium, ensuring a minimum cell density of 3×10⁶ cells/mL.
  6. Aliquot 1 mL of the cell suspension into each pre-labeled cryovial.
  7. Place the cryovials into a CoolCell® container and store at -80°C overnight for controlled-rate cooling.
  8. Transfer the cryovials to the liquid nitrogen for long-term storage the following day.

References

  1. Bahng I CCR-CCL axes as key upstream influencers of pancreatic ductal adenocarcinoma: CCR2-CCL2, CCR5-CCL5, CCR4-CCL17/22, CCR6-CCL20, CCR7-CCL19/21. Frontiers in immunology. 2026;17:1713123. PMID: 41694374. doi: 10.3389/fimmu.2026.1713123.
  2. Elhadary M, Elsayed B, Elshoeibi AM et al. The Clinicopathological and Prognostic Value of CCR7 Expression in Breast Cancer Throughout the Literature: A Systematic Review and Meta-Analysis. Biomedicines. 2025 Apr 21;13(4):. PMID: 40299690. doi: 10.3390/biomedicines13041007.
  3. Meloun A, León B Beyond CCR7: dendritic cell migration in type 2 inflammation. Frontiers in immunology. 2025;16:1558228. PMID: 40093008. doi: 10.3389/fimmu.2025.1558228.

Use License Agreement

Research Use Only.
Not for use in diagnostic procedures or therapeutic applications.
Redistribution of the cell line or its derivatives is prohibited without prior written permission from Kyinno Biotechnology.